Cenveo Announces Conference Call for Third Quarter Results
Get Alerts CVO Hot Sheet
Join SI Premium – FREE
STAMFORD, Conn., Nov. 10, 2015 /PRNewswire/ -- Cenveo, Inc. (NYSE: CVO) announced today that it will release its third quarter 2015 results on Wednesday, November 18, 2015 after market close and will host a conference call at 9:00 A.M Eastern Time on Thursday, November 19, 2015 to discuss those results. A live webcast of the call will be accessible on Cenveo's website: www.cenveo.com.
On or about Wednesday, November 18, 2015, Cenveo also expects to file its first and second quarter 2015 amended Form 10-Qs and its third quarter Form 10-Q, all of which will have been reviewed by its new auditor firm, BDO. With these filings, Cenveo anticipates to be fully compliant once again with NYSE and SEC filing and notification requirements.
Cenveo (NYSE: CVO), world headquartered in Stamford, Connecticut, is a leading global provider of print and related resources, offering world-class solutions in the areas of custom boxes, custom labels, shrink sleeve labels, envelopes, commercial print, content management and publisher solutions. The company provides a one-stop offering through services ranging from design and content management to fulfillment and distribution. With a worldwide distribution platform, we pride ourselves on delivering quality solutions and service every day for our more than 100,000 customers. For more information please visit us at www.cenveo.com.
Inquiries from analysts and investors should be directed to Ayman Zameli at (203) 595-3063.
Logo - http://photos.prnewswire.com/prnh/20070618/CENVEOLOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cenveo-announces-conference-call-for-third-quarter-results-300176229.html
SOURCE Cenveo, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
- Phio Pharmaceuticals Corp. (PHIO) Reports Intratumoral Injection of PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
- INmune Bio (INMB) Prices 572K Share Offering at $8.32/sh
Create E-mail Alert Related Categories
Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!